… minocycline does not reach a steady state in such a short period of time, suggesting that
neuroprotective levels were not … patients due to reported benefits in experimental models of HD. …

… as other cellular processes, is disrupted in Huntington's disease (HD). Treatments that … in
model organisms. However, agents that selectively target the disease-relevant HDACs have not …

… that the vehicle did not influence the effect of minocycline, in … minocycline was not affected
by vehicle. When saline was used as the vehicle, the mean total injury score in the minocycline…

… , Parkinson diseases, and amyotrophic lateral sclerosis. However, … that minocycline does
not always present beneficial actions. For instance, in an in vivo model of Huntington's disease, …

… to play a major role in the pathogenesis of Huntington's Disease (HD). PK11195 is a ligand
… Minocycline is a tetracycline derivative which inhibits microglial activation and expression of …

… doxycycline (another tetracycline derivative) or minocycline … to inhibit aggregation in vitro,
had no effect on the loss of body … Minocycline and doxycycline are not beneficial in a model of …

… This did not model the disease but instead showed … Minocycline inhibits caspase-1 and
caspase-3 expression and delays mortality in a transgenic mouse model of Huntington disease…

… Doxycycline and minocycline have been tested as potential therapeutics in mouse models of
Huntington disease … be a more accessible target for doxycycline, which would need to cross …

… models of neurodegenerative disease. We investigated the neuroprotective potential of
doxycycline in a Drosophila model … of doxycycline to Aβ42-expressing flies did not improve their …

… inhibits caspase-1 and caspase-3 expression and delays mortality in a transgenic mouse
model of Huntington disease. Nature Med 6:797–801 Clark WM, Calcagno FA, Gabler WL, …